Montreal-based company, The Good Shroom (TSTX:MUSH), announced its financial results for the quarter ended on April 30, 2024. The report includes results for the subsidiary Teonan Biomedical Inc. “The consistent profitability this quarter, despite a challenging market, highlights our focused execution and strategic adaptations,” stated Eric Ronsse, CEO. This quarter marks the company’s fifth consecutive profitable quarter, emphasizing its resilience and operational efficiency. Year-Over-Year Financial Highlights: Gross Revenue: The company reported a slight decrease in quarterly sales, amounting to $1,135,991 compared to $1,266,186 in the same quarter last year. This marks a decrease of approximately 10.3% Net Profit: There was an improvement in net ...